AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06469788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences
Description: Participants will watch video focused on the importance of receipt of updated COVID-19 vaccination in patients with AIRD
Study NCT06469788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video on the importance of good oral health for patients with AIRD
Description: Participants will watch video on the importance of good oral health in AIRD patients.
Study NCT06469788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure on COVID-19 vaccination in AIRD patients
Description: Participants
Study NCT06469788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Participants will receive phone calls from patient navigators to provide support and information for receipt of updated COVID-19 vaccination in patients with AIRD
Study NCT06469788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brochure on the importance of good oral health in AIRD patients
Description: Participants will receive a brochure on the importance of good oral health in AIRD patients.
Study NCT05186753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezuclastinib Tablets (Formulation A)
Description: Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
Study NCT05186753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezuclastinib Tablets (Formulation B)
Description: Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
Study NCT05186753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo will be administered orally, once daily continuously for 28-day cycles
Study NCT05139017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg
Study NCT05139017 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: IV Infusion 375 mg/m\^2
Study NCT05139017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV Infusion 375 mg/m\^2
Study NCT05139017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV Infusion 1000 mg/m\^2
Study NCT05139017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV Infusion 1000 mg/m\^2
Study NCT05139017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV Infusion 100 mg/m\^2
Study NCT05139017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Infusion 100 mg/m\^2
Study NCT05139017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: IV Infusion 90 mg/m\^2
Study NCT05139017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: IV Infusion 90 mg/m\^2
Study NCT06208150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered as a SC injection.
Study NCT06208150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally.
Study NCT06208150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally.
Study NCT06208150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered as a SC injection.
Study NCT06208150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elotuzumab
Description: Elotuzumab will be administered intravenously.
Study NCT06208150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered either orally or intravenously.
Study NCT06208150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered either orally or intravenously.
Study NCT06208150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib will be administered as a SC injection.
Study NCT05386914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 1 mg of Sirolimus taken orally once a day for 4 weeks.
Study NCT05386914 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: 1 mg of Sirolimus taken orally once a day for 4 weeks.
Study NCT04799015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10mg IV
Study NCT04799015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10mg
Description: Metoclopramide 10mg IV
Study NCT04799015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide 10mg
Description: Metoclopramide 10mg IV
Study NCT05901636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFLUENZA G1 mHA
Description: INFLUENZA G1 mHA will be administered intramuscularly.
Study NCT05901636 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intramuscularly.
Study NCT05901636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Al(OH)3
Description: Al(OH)3 will be administered intramuscularly.
Study NCT04829318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine will be self-administered as nasal spray.
Study NCT04829318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI/SNRI
Description: Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
Study NCT04593732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STERN FIX (Sternal Stabilization System)
Description: Sternotomy closure with STERN FIX and supplemented with wires
Study NCT04610294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functioning Aerus air filtration/sterilization
Description: Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be active and will be sealed to prevent operating room personnel from opening the system and determining a unit's status.
Study NCT04610294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deactivated Aerus air filtration/sterilization
Description: Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be inactivated and will be sealed to prevent operating room personnel from opening the system and determining a unit's status. Units will be inactivated by removing the activated carbon, high-efficiency particulate filter, and ionization chamber. However, the fan will remain active as will the run lights.
Study NCT06315231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone dexborneol sublingual tablet
Description: Patients will receive one edaravone dexborneol sublingual tablet twice daily for 24 weeks
Study NCT06315231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive one placebo twice daily for 24 weeks
Study NCT05624125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: Two 70 ml beetroot juice drinks daily for 4 months.
Study NCT05624125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two 70 ml placebo drinks daily for 4 months.
Study NCT04858490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Symptom-triggered diazepam treatment: 10 or 20mg, at the clinician's discretion
Study NCT00927121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset
Description: The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system
Study NCT04496895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: consume 1 sachet per day for 2 months
Study NCT04496895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: orange peel fermentation
Description: consume 1 sachet per day for 2 months
Study NCT05658224 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education on effects of Exercise-induced hypoalgesia from exercise
Description: Educational session with participants
Study NCT00927121 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset
Description: The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system
Study NCT04562441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib: 5 mg bd po Day 1 to Day 28
Study NCT04778943 — intervention group
Intervention type: OTHER
Intervention: Surgery(OLIF and MIS-TLIF)
Description: oblique lateral interbody fusion (OLIF); minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
Study NCT04562441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab: 10 mg/kg Day 1 to Day 15 every 4 weeks
Study NCT04750798 — intervention group
Intervention type: DEVICE
Intervention: BWI Medical Device
Description: Participants will be treated with commercially approved BWI medical devices following routine clinical practice. No specific intervention will be observed for this study.
Study NCT04750798 — intervention group
Intervention type: DEVICE
Intervention: Varipulse Catheter
Description: Participants treated with Varipulse Catheter in the main study will be part of the VARIPURE sub-study. No specific intervention will be observed for this study.
Study NCT05306314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: TREATAPROST
Description: oral administration before meals 30 minutes
Study NCT06094283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YCT-529
Description: Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg
Study NCT06094283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YCT-529 Placebo
Description: YCT-529 Placebo
Study NCT06220396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right Heart Catheterization with Hemodynamics and Limited Echocardiogram
Description: Right Heart Catheterization (RHC) with Hemodynamics and Limited Echocardiogram is an invasive procedure that involves insertion of a catheter through a blood vessel in the neck, groin, or arm to the right side of the heart. Hemodynamic measurements such as the blood pressure inside the veins, heart, and arteries as well as measurements of blood flow and how much oxygen is in the blood will be completed during the catheterization procedure. It is a way to see how well the heart is working during your procedure. During the RHC procedure a limited echocardiogram, using ultrasound waves, will be collected to evaluate the structure and function of the heart.~All measurements will be conducted at rest and during exercise using a supine cycle ergometer
Study NCT06220396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body. CMR Imaging will assess myocardial structure, function, and fat content.~An additional limited MRI sequence of the the abdomen and one sequence in the thigh will be used to evaluate for visceral adipose tissue (VAT) as a measurement of body composition.
Study NCT06220396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray absorptiometry (DEXA) scan
Description: A DEXA scan measures the amount of fat in the body using an x-ray that measures bone, calcium and fat.
Study NCT05991700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freeze-Dried California Table Grape
Description: Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
Study NCT05991700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
Study NCT06422845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dissolve AV Peripheral Scoring Drug-coated Balloon
Description: Subjects in the test group are treated with Dissolve AV Peripheral Scoring Drug-coated Balloon
Study NCT05641688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: The radioligand, \[18F\]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%
Study NCT03847311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: This group will receive supplies for 3 months of sulfasalazine at an initial dose of 0.5 gram three times a day for a week then at a dose of 1 gram three times a day for the remainder of the 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
Study NCT03847311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: This group will receive supplies for 3 months of sugar pills three times a day for 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
Study NCT06116786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-86974680
Description: JNJ-86974680 will be administered.
Study NCT06116786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.
Study NCT06116786 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be administered.
Study NCT06028438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously.
Study NCT06028438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered intravenously.
Study NCT06028438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab
Description: Certolizumab will be administered subcutaneously.
Study NCT06028438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab
Description: Certolizumab will be administered subcutaneously.
Study NCT05552339 — intervention group
Intervention type: DRUG
Intervention: Finerenone (Kerendia, BAY94-8862)
Description: Following the physicians' decision.
Study NCT05552339 — intervention group
Intervention type: DRUG
Intervention: Type 2 DM drugs
Description: Following the physicians' decision
Study NCT05078060 — intervention group
Intervention type: BIOLOGICAL
Intervention: Quadrivalent Influenza Vaccine
Description: Intramuscular or subcutaneous administration
Study NCT05529615 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: detection of ctDNA
Description: the ctDNA will be detected during the treatment and served as the andomization basis
Study NCT06014593 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: expirogram
Description: Recovery of heart failure data (left ventricular ejection fraction LVEF on cardiac echography (in mL), VO²max during, maximal cardio-pulmonary exercise test, plethysmographic spirometry, carbon monoxide transfer, NT-ProBNP assay,), clinical examination and finally expirogram with the device measuring the 4 exhaled biomarkers (CO/NO/Acetone/Isoprene).
Study NCT06411925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atock Dry Syrup
Description: Dry syrup, TID
Study NCT06411925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry syrup, TID
Study NCT04722744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: screwmented metal frameworks
Description: Intervention group: in which the edentulous area will be restored with 3-implant, screwmented CAD/CAM frameworks constructed based on planned implant positions
Study NCT04722744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: screwmented metal frameworks
Description: Intervention group: in which the edentulous area will be restored with 3-implant, screwmented CAD/CAM frameworks constructed based on planned implant positions
Study NCT05078060 — intervention group
Intervention type: BIOLOGICAL
Intervention: High-Dose Quadrivalent Influenza Vaccine
Description: Intramuscular administration
Study NCT04822844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Essential Oil
Description: Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
Study NCT04822844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger Essential Oil
Description: Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
Study NCT06507371 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: node-sparing modified short-course radiotherapy
Description: radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
Study NCT06507371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PD-1 antibody
Description: PD-1 antibody (Tislelizumab): 200mg d1 q3w
Study NCT06507371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Tislelizumab): 200mg d1 q3w
Study NCT06507371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Study NCT06507371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Study NCT06507371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w
Study NCT06507371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w
Study NCT06205719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofol
Description: sedation
Study NCT06205719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remazolam
Description: sedation
Study NCT06205719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remazolam
Description: sedation
Study NCT06205719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Description: antagonism
Study NCT06205719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 2ug/kg Remifentanil
Study NCT06205719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 2ug/kg Remifentanil
Study NCT06507371 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: standard short-course radiotherapy
Description: radiation targeting the tumor bed and surrounding tumor-draining lymph nodes: 25Gy/5Fx
Study NCT04924309 — intervention group
Intervention type: OTHER
Intervention: Exposure: donor sperm
Description: One group use donor sperm through the process of assisted reproduction and the other uses husband's semen.
Study NCT06094556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1826
Description: dose is calculated based on the subjects' baseline weight.
Study NCT04611191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Team Sports
Description: The intervention involves team sports in sports clubs in local municipalities